CH650799A5 - Verfahren zur herstellung von lipopolysacchariden mit antitumoraktivitaet und immunotherapeutische mittel gegen tumore. - Google Patents
Verfahren zur herstellung von lipopolysacchariden mit antitumoraktivitaet und immunotherapeutische mittel gegen tumore. Download PDFInfo
- Publication number
- CH650799A5 CH650799A5 CH5128/80A CH512880A CH650799A5 CH 650799 A5 CH650799 A5 CH 650799A5 CH 5128/80 A CH5128/80 A CH 5128/80A CH 512880 A CH512880 A CH 512880A CH 650799 A5 CH650799 A5 CH 650799A5
- Authority
- CH
- Switzerland
- Prior art keywords
- lipopolysaccharide
- mol
- arabinomannan
- acid
- fatty acids
- Prior art date
Links
- 239000002158 endotoxin Substances 0.000 title claims description 54
- 229920006008 lipopolysaccharide Polymers 0.000 title claims description 54
- 206010028980 Neoplasm Diseases 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000002955 immunomodulating agent Substances 0.000 title description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 36
- 239000000194 fatty acid Substances 0.000 claims description 36
- 229930195729 fatty acid Natural products 0.000 claims description 36
- 150000004665 fatty acids Chemical class 0.000 claims description 34
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 34
- GUSANBRNBREBPL-TZTIVRRBSA-N alpha-D-Ara-(1->5)-alpha-D-Ara-(1->3)-[alpha-D-Ara-(1->5)]-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->2)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)]-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man Chemical compound OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@H]3[C@H](O)[C@@H](OC[C@H]4O[C@H](OC[C@H]5O[C@H](O[C@H]6[C@@H](O)[C@H](O)[C@@H](CO[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)O[C@@H]6OC[C@H]6O[C@H](OC[C@H]7O[C@H](OC[C@H]8O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H](O)[C@@H]7O)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)O[C@@H]3CO[C@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GUSANBRNBREBPL-TZTIVRRBSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 24
- 210000005056 cell body Anatomy 0.000 claims description 21
- 235000021314 Palmitic acid Nutrition 0.000 claims description 17
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 14
- -1 arabinomannan polysaccharide Chemical class 0.000 claims description 11
- 150000002772 monosaccharides Chemical class 0.000 claims description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 2
- 229940041290 mannose Drugs 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- BEOUGZFCUMNGOU-UHFFFAOYSA-N tuberculostearic acid Chemical compound CCCCCCCCC(C)CCCCCCCCC(O)=O BEOUGZFCUMNGOU-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 229920000057 Mannan Polymers 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 9
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 9
- 101150019464 ARAF gene Proteins 0.000 description 8
- 101100071254 Mus musculus Hnrnpul2 gene Proteins 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 6
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ALNDFFUAQIVVPG-HSUXUTPPSA-N (2s,3r,4r)-3,4,5-trihydroxy-2-methoxypentanal Chemical compound CO[C@H](C=O)[C@H](O)[C@H](O)CO ALNDFFUAQIVVPG-HSUXUTPPSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 4
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- HUEBIMLTDXKIPR-UHFFFAOYSA-N methyl heptadecanoate Chemical compound CCCCCCCCCCCCCCCCC(=O)OC HUEBIMLTDXKIPR-UHFFFAOYSA-N 0.000 description 4
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- JDQXPMXNBAIAOW-QYNIQEEDSA-N (2S,3R,4R)-2,4-dihydroxy-3,5-dimethoxypentanal Chemical compound COC[C@@H](O)[C@@H](OC)[C@H](O)C=O JDQXPMXNBAIAOW-QYNIQEEDSA-N 0.000 description 2
- IXLOVRRUGOPNHY-BWZBUEFSSA-N (2S,3R,4R)-4-hydroxy-2,3,5-trimethoxypentanal Chemical compound COC[C@@H](O)[C@@H](OC)[C@H](OC)C=O IXLOVRRUGOPNHY-BWZBUEFSSA-N 0.000 description 2
- MLMZDKFLNSRHDV-HSUXUTPPSA-N (2r,3r,4r)-2-methylpentane-1,2,3,4,5-pentol Chemical compound OC[C@](O)(C)[C@H](O)[C@H](O)CO MLMZDKFLNSRHDV-HSUXUTPPSA-N 0.000 description 2
- SXYJOSUUQAWDDF-DBRKOABJSA-N (2r,3r,4r,5r)-3-methylhexane-1,2,3,4,5,6-hexol Chemical compound OC[C@@H](O)[C@](O)(C)[C@H](O)[C@H](O)CO SXYJOSUUQAWDDF-DBRKOABJSA-N 0.000 description 2
- CCLARULDIPFTCP-VHQZISHXSA-N (2r,3r,4r,5r)-heptane-1,2,3,4,5,6-hexol Chemical compound CC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CCLARULDIPFTCP-VHQZISHXSA-N 0.000 description 2
- SKCKOFZKJLZSFA-SJLAOBFJSA-N (2r,3s,4r)-hexane-1,2,3,4,5-pentol Chemical compound CC(O)[C@@H](O)[C@@H](O)[C@H](O)CO SKCKOFZKJLZSFA-SJLAOBFJSA-N 0.000 description 2
- USFHVNKTXVCTQN-MVIOUDGNSA-N (2r,3s,4r,5r)-2-methylhexane-1,2,3,4,5,6-hexol Chemical compound OC[C@](O)(C)[C@@H](O)[C@H](O)[C@H](O)CO USFHVNKTXVCTQN-MVIOUDGNSA-N 0.000 description 2
- GKMXSVIYNRJGBP-RFZPGFLSSA-N (2r,4r)-3-methylpentane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)C(O)(C)[C@H](O)CO GKMXSVIYNRJGBP-RFZPGFLSSA-N 0.000 description 2
- RTNZMCCAPWYVBP-FSDSQADBSA-N (2s,3r,4r)-4,5-dihydroxy-2,3-dimethoxypentanal Chemical compound CO[C@H](C=O)[C@H](OC)[C@H](O)CO RTNZMCCAPWYVBP-FSDSQADBSA-N 0.000 description 2
- IFKTXTIJQDZVLX-WCTZXXKLSA-N (2s,3r,4r,5r)-2,5,6-trihydroxy-3,4-dimethoxyhexanal Chemical compound OC[C@@H](O)[C@@H](OC)[C@H](OC)[C@H](O)C=O IFKTXTIJQDZVLX-WCTZXXKLSA-N 0.000 description 2
- OHWRFXMAKSGOGG-FNCVBFRFSA-N (2s,3r,4r,5r)-2,5-dihydroxy-3,4,6-trimethoxyhexanal Chemical compound COC[C@@H](O)[C@@H](OC)[C@H](OC)[C@H](O)C=O OHWRFXMAKSGOGG-FNCVBFRFSA-N 0.000 description 2
- LOODZAPIPITKBN-FNCVBFRFSA-N (2s,3s,4r,5r)-5,6-dihydroxy-2,3,4-trimethoxyhexanal Chemical compound CO[C@H](C=O)[C@@H](OC)[C@H](OC)[C@H](O)CO LOODZAPIPITKBN-FNCVBFRFSA-N 0.000 description 2
- LMWNQPUYOLOJQP-ZYUZMQFOSA-N (2s,3s,4r,5r)-5-hydroxy-2,3,4,6-tetramethoxyhexanal Chemical compound COC[C@@H](O)[C@@H](OC)[C@H](OC)[C@H](OC)C=O LMWNQPUYOLOJQP-ZYUZMQFOSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- NWKYZYGOSPOKDY-UHFFFAOYSA-N n,n-dimethylformamide;pyridine Chemical compound CN(C)C=O.C1=CC=NC=C1 NWKYZYGOSPOKDY-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- NGEZPLCPKXKLQQ-VOTSOKGWSA-N (e)-4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(\C=C\C(C)=O)=C1 NGEZPLCPKXKLQQ-VOTSOKGWSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8468179A JPS568320A (en) | 1979-07-04 | 1979-07-04 | Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH650799A5 true CH650799A5 (de) | 1985-08-15 |
Family
ID=13837428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH5128/80A CH650799A5 (de) | 1979-07-04 | 1980-07-03 | Verfahren zur herstellung von lipopolysacchariden mit antitumoraktivitaet und immunotherapeutische mittel gegen tumore. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US4329452A (enExample) |
| JP (1) | JPS568320A (enExample) |
| CA (1) | CA1132047A (enExample) |
| CH (1) | CH650799A5 (enExample) |
| ES (1) | ES493061A0 (enExample) |
| FR (1) | FR2484258A1 (enExample) |
| IT (1) | IT1132168B (enExample) |
| SU (1) | SU1232124A3 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5718619A (en) * | 1980-07-10 | 1982-01-30 | Chisato Maruyama | Tumor immunotherapy agent containing lipopolysaccharide as active principle |
| JPS59161320A (ja) * | 1983-03-04 | 1984-09-12 | Maruyama Chisato | リポ多糖体およびその製造法 |
| US4612304A (en) * | 1985-06-11 | 1986-09-16 | Ss Pharmaceutical Co., Ltd. | Antitumor formulation containing lipopolysaccharide with trehalose derivatives |
| US4818751A (en) * | 1985-07-02 | 1989-04-04 | Zeria Shinyaku Kogyo Kabushiki Kaisha | Cosmetics |
| EP0295749A1 (en) * | 1987-06-15 | 1988-12-21 | Duphar International Research B.V | Sulpholipopolysaccharides as stimulators of the non-specific defence mechanism |
| US4798369A (en) * | 1987-11-03 | 1989-01-17 | The Firestone Tire & Rubber Company | Ultrasonic air spring system |
| US5853737A (en) * | 1992-12-10 | 1998-12-29 | Brigham And Women's Hospital | Method for inducing a CD1-restricted immune response |
| US6238676B1 (en) * | 1992-12-10 | 2001-05-29 | Brigham And Women's Hospital | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US5712123A (en) * | 1994-10-07 | 1998-01-27 | Board Of Trustees Of The University Of Illinois | Mixture having antitumor activities |
| WO1998056941A1 (en) * | 1995-12-12 | 1998-12-17 | Tai Ho Chung | Carbohydrate complex extracted from mycobacterium tuberculosis and process for the preparation thereof |
| US5869645A (en) * | 1997-10-15 | 1999-02-09 | Board Of Trustees Of The University Of Illinois | Method for isolating high molecular weight antineoplastic glycans using urea |
| NZ505538A (en) * | 2000-07-03 | 2004-12-24 | Malaghan Inst Of Medical Res | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma |
| US8034359B2 (en) | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| PL1765391T3 (pl) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US20070161546A1 (en) * | 2005-12-15 | 2007-07-12 | Colm King | Methods and compositions for treatment of cancer |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| JP2015157763A (ja) * | 2012-05-28 | 2015-09-03 | エヌエーアイ株式会社 | 認知症の治療剤及び予防剤 |
| EP3125763A4 (en) | 2014-03-31 | 2017-12-13 | University of Utah Research Foundation | Fluid analysis device and associated systems and methods |
| CA3254723A1 (en) | 2014-05-02 | 2025-04-15 | Qu Biologics Inc | ANTIMICROBIAL IMMUNOMODULATION |
| EP4226939A4 (en) * | 2020-10-09 | 2024-11-13 | Zeria Pharmaceutical Co., Ltd. | NEW USE OF A MYCOBACTERIUM TUBERCULOSIS EXTRACT |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1188519A (en) * | 1966-10-27 | 1970-04-15 | Wellcome Found | Method for the Purification of Lipopolysaccharides |
| NL7308450A (enExample) * | 1972-06-20 | 1973-12-27 | ||
| FR2227862A1 (en) * | 1973-05-04 | 1974-11-29 | Anvar | Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues |
| JPS5132794A (en) * | 1974-06-20 | 1976-03-19 | Anvar | Koshuyokoirusu oyobi ajubantokatsuseiojusuru maikobakuteriumufurakushonnoseiseiho |
-
1979
- 1979-07-04 JP JP8468179A patent/JPS568320A/ja active Granted
-
1980
- 1980-05-06 US US06/147,127 patent/US4329452A/en not_active Expired - Lifetime
- 1980-06-09 FR FR8012794A patent/FR2484258A1/fr active Granted
- 1980-07-03 CA CA355,290A patent/CA1132047A/en not_active Expired
- 1980-07-03 CH CH5128/80A patent/CH650799A5/de not_active IP Right Cessation
- 1980-07-03 SU SU802943651A patent/SU1232124A3/ru active
- 1980-07-03 IT IT23219/80A patent/IT1132168B/it active
- 1980-07-03 ES ES493061A patent/ES493061A0/es active Granted
-
1981
- 1981-08-18 US US06/293,999 patent/US4394502A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES8105783A1 (es) | 1981-06-16 |
| US4329452A (en) | 1982-05-11 |
| JPS568320A (en) | 1981-01-28 |
| JPS6256843B2 (enExample) | 1987-11-27 |
| IT8023219A0 (it) | 1980-07-03 |
| CA1132047A (en) | 1982-09-21 |
| US4394502A (en) | 1983-07-19 |
| FR2484258A1 (fr) | 1981-12-18 |
| ES493061A0 (es) | 1981-06-16 |
| SU1232124A3 (ru) | 1986-05-15 |
| FR2484258B1 (enExample) | 1984-11-30 |
| IT1132168B (it) | 1986-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH650799A5 (de) | Verfahren zur herstellung von lipopolysacchariden mit antitumoraktivitaet und immunotherapeutische mittel gegen tumore. | |
| DE69032206T2 (de) | Lipid-a-derivate sowie deren verwendungen | |
| DE69030880T2 (de) | Zusammensetzung zur Stimulierung des Immunsystems | |
| Gottschalk | The chemistry and biology of sialic acids and related substances | |
| DE3407823C2 (enExample) | ||
| Anderson | The chemistry of the lipoids of the tubercle bacillus and certain other microorganisms | |
| DE69324859T2 (de) | Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis | |
| DE2331144A1 (de) | Wasserloesliche extrakte von mycobacterien | |
| DE69627652T2 (de) | Verbesserte meningokokken polysaccharid-konjugat vakzine | |
| EP0220387B1 (de) | Konjugatimpfstoffe gegen Infektionen durch gramnegative Bakterien, Verfahren zu deren Herstellung sowie Verwendung derselben | |
| DE2638762A1 (de) | Wasserloesliche adjuvantien, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE69333723T2 (de) | Pharmazeutische zubereitung auf der basis von rhamnolipid gegen dermatologische erkrankungen | |
| DE2659808C3 (de) | Proteingebundene Polysaccharide und deren Verwendung zur Bekämpfung von Tumoren | |
| DE69228128T2 (de) | Glycosphingolipide | |
| DE69327284T2 (de) | Neutrale Lipide aus dem Endosperm von Coix lacryma jobi und sie enthaltende Zusammensetzungen | |
| DE69330252T2 (de) | Zusammensetzungen für die regulation der cytokinaktivität | |
| DD202168A5 (de) | Verfahren zur herstellung eines glycoproteins | |
| GB2076418A (en) | Hydrolyzed polysaccharide | |
| Goren | Cord factor revisited: a tribute to the late Dr. Hubert Bloch | |
| DE69810024T2 (de) | Inhibitor der immunoglobulin e antikörpererzeugung zur behandlung von typ i allergie-verwandten krankheiten | |
| DE3048699C2 (de) | Immuntherapeutisches Mittel gegen Tumore, enthaltend als wirksame Komponente ein Lipopolysaccharid | |
| JPH05500817A (ja) | マイコバクテリウムケロナエの極性糖ペプチド脂質に基づく免疫刺激薬 | |
| DE69724156T2 (de) | Aus mycobacterium tuberculosis extrahierter kohlenwasserstoffkomplex und verfahren zu dessen herstellung | |
| EP0991773B1 (en) | Carbohydrate complex extracted from mycobacterium tuberculosis and process for the preparation thereof | |
| DE2408724A1 (de) | Biologische extrakte und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |